New research led by the Icahn School of Medicine at Mount Sinai published online in The Journal of the American Medicine Association (JAMA) showed that a higher percentage of stable, opioid - dependent patients given six - month buprenorphine implants remained
abstinent compared to patients given the medication sublingually.
Not exact matches
Of those who attended at least 27 weeks of AA meetings during the first year, 67 percent were
abstinent at the 16 - year follow - up,
compared with 34 percent of those who did not participate in AA.
The researchers found that baclofen led to higher
abstinent rates
compared with placebo, and that eight individuals would need to be treated with baclofen for one to remain
abstinent due to the medication.
The results were promising — almost 90 % of the addicted persons who received the naltrexone shot remained
abstinent during the test period,
compared to just over 60 % of the control group.